China biotech deals hit record as innovative drugs draw interest of multinationals (opens in new tab)

<p>The cross-border outlicensing activities of Chinese biotech firms reached a record transaction value of US$60 billion in the first quarter of 2026, driven by multinational pharmaceutical companies’ growing appetite for the country’s promising drug candidates. The deal value represented a 73 per cent jump from the same period a year earlier, and accounted for nearly [&#8230;]</p> <p>The post <a href=" biotech deals hit record as innovative drugs draw interest of multinationals</a> appeared ...